Daniel Cimbora

3.7k total citations · 1 hit paper
36 papers, 2.2k citations indexed

About

Daniel Cimbora is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Daniel Cimbora has authored 36 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 13 papers in Pathology and Forensic Medicine and 9 papers in Immunology. Recurrent topics in Daniel Cimbora's work include Multiple Sclerosis Research Studies (11 papers), Peripheral Neuropathies and Disorders (7 papers) and Genomics and Chromatin Dynamics (6 papers). Daniel Cimbora is often cited by papers focused on Multiple Sclerosis Research Studies (11 papers), Peripheral Neuropathies and Disorders (7 papers) and Genomics and Chromatin Dynamics (6 papers). Daniel Cimbora collaborates with scholars based in United States, Germany and Japan. Daniel Cimbora's co-authors include Mark Groudine, Andreas Reik, Dirk Schübeler, David I. K. Martin, Claire Francastel, Elliot Epner, Agnes Telling, Thaylon Davis, Hans‐Georg Kräusslich and Diane M. Ward and has published in prestigious journals such as Cell, Genes & Development and Molecular Cell.

In The Last Decade

Daniel Cimbora

35 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Protein Network of HIV Budding

2003 689 citations Uta K. von Schwedler, Bárbara Müller et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Cimbora United States	21	1.4k	421	307	276	267	36	2.2k
Yegor Vassetzky France	35	2.7k 1.9×	168 0.4×	232 0.8×	159 0.6×	404 1.5×	160	3.4k
Meg Trahey United States	17	1.7k 1.2×	524 1.2×	321 1.0×	165 0.6×	201 0.8×	22	2.4k
Jamal Tazi France	43	5.3k 3.7×	284 0.7×	248 0.8×	218 0.8×	457 1.7×	87	6.0k
Terry Copeland United States	15	1.9k 1.3×	518 1.2×	171 0.6×	101 0.4×	157 0.6×	19	2.5k
Andrew Y. Choo United States	20	1.6k 1.1×	170 0.4×	558 1.8×	285 1.0×	107 0.4×	29	2.6k
François Dautry France	30	2.2k 1.6×	218 0.5×	404 1.3×	38 0.1×	269 1.0×	61	3.1k
Cheng-Ming Chiang United States	36	4.1k 2.9×	184 0.4×	392 1.3×	223 0.8×	491 1.8×	62	5.1k
Stefanie Jäger United States	14	954 0.7×	619 1.5×	250 0.8×	369 1.3×	100 0.4×	17	2.0k
R Ben-Levy Israel	18	1.5k 1.1×	226 0.5×	233 0.8×	108 0.4×	213 0.8×	18	2.3k
Anup Dey United States	28	3.4k 2.4×	217 0.5×	742 2.4×	128 0.5×	516 1.9×	47	4.2k

Countries citing papers authored by Daniel Cimbora

Since Specialization

Citations

This map shows the geographic impact of Daniel Cimbora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Cimbora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Cimbora more than expected).

Fields of papers citing papers by Daniel Cimbora

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Cimbora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Cimbora. The network helps show where Daniel Cimbora may publish in the future.

Co-authorship network of co-authors of Daniel Cimbora

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Cimbora. A scholar is included among the top collaborators of Daniel Cimbora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Cimbora. Daniel Cimbora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bennett, Jeffrey L., Sean J. Pittock, Friedemann Paul, et al.. (2024). B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity. Annals of Clinical and Translational Neurology. 11(10). 2792–2798. 4 indexed citations

Cree, Bruce, Ho Jin Kim, Brian G. Weinshenker, et al.. (2024). Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. The Lancet Neurology. 23(6). 588–602. 20 indexed citations

Aktaş, Orhan, Hans‐Peter Hartung, William A. Rees, et al.. (2023). Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. Journal of Neurology Neurosurgery & Psychiatry. 94(9). 757–768. 20 indexed citations

Kim, Ho Jin, Orhan Aktaş, Kristina R. Patterson, et al.. (2023). Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism. Annals of Clinical and Translational Neurology. 10(12). 2413–2420. 8 indexed citations

Weinshenker, Brian G., Dean M. Wingerchuk, Ari Green, et al.. (2023). Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum. Multiple Sclerosis Journal. 29(8). 945–955. 5 indexed citations

Marignier, Romain, Sean J Pittock, Friedemann Paul, et al.. (2021). AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders. 57. 103356–103356. 24 indexed citations

Cree, Bruce, Jeffrey L. Bennett, Brian G. Weinshenker, et al.. (2021). Long Term Safety Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial (2283). Neurology. 96(15_supplement). 2 indexed citations

Cree, Bruce, Jeffrey L. Bennett, Brian G. Weinshenker, et al.. (2021). Long Term Efficacy Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial (2329). Neurology. 96(15_supplement). 3 indexed citations

Li, Yan, Holly Kimko, Bing Wang, et al.. (2021). Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis. Clinical Pharmacokinetics. 61(3). 387–400. 13 indexed citations

10.

Forsthuber, Thomas G., Daniel Cimbora, John N. Ratchford, Eliezer Katz, & Olaf Stüve. (2018). B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Therapeutic Advances in Neurological Disorders. 11. 1276983265–1276983265. 90 indexed citations

11.

Schiopu, Elena, Soumya Chatterjee, Vivien Hsu, et al.. (2016). Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Research & Therapy. 18(1). 131–131. 60 indexed citations

12.

Bursavich, Matthew G., Mark D. Shenderovich, Kraig M. Yager, et al.. (2013). Novel Mps1 kinase inhibitors: From purine to pyrrolopyrimidine and quinazoline leads. Bioorganic & Medicinal Chemistry Letters. 23(24). 6829–6833. 13 indexed citations

13.

Lockman, Jeffrey W., Rosann Robinson, Patricia A. Ormonde, et al.. (2011). Oxindole derivatives as inhibitors of TAK1 kinase. Bioorganic & Medicinal Chemistry Letters. 21(6). 1724–1727. 24 indexed citations

14.

Terry-Lorenzo, Ryan T., et al.. (2011). Abstract 2551: The Nampt inhibitor MPC-9528 synergizes with DNA damaging agents. Cancer Research. 71(8_Supplement). 2551–2551. 1 indexed citations

15.

Williams, Brandi L., Daniel Cimbora, Vijay Baichwal, et al.. (2009). Abstract #LB-204: MPI-0479605: A novel small molecule inhibitor of the mitotic kinase TTK with anti-tumor activity in pre-clinical models. Cancer Research. 69. 1 indexed citations

16.

Schwedler, Uta K. von, Bárbara Müller, Diane M. Ward, et al.. (2003). The Protein Network of HIV Budding. Cell. 114(6). 701–713. 689 indexed citations breakdown →

17.

Cimbora, Daniel & Mark Groudine. (2001). The Control of Mammalian DNA Replication. Cell. 104(5). 643–646. 37 indexed citations

18.

Reik, Andreas, Agnes Telling, Galynn Zitnik, et al.. (1998). The Locus Control Region Is Necessary for Gene Expression in the Human β-Globin Locus but Not the Maintenance of an Open Chromatin Structure in Erythroid Cells. Molecular and Cellular Biology. 18(10). 5992–6000. 143 indexed citations

19.

Epner, Elliot, Andreas Reik, Daniel Cimbora, et al.. (1998). The β-Globin LCR Is Not Necessary for an Open Chromatin Structure or Developmentally Regulated Transcription of the Native Mouse β-Globin Locus. Molecular Cell. 2(4). 447–455. 170 indexed citations

20.

Cimbora, Daniel & Shigeru Sakonju. (1995). Drosophila Midgut Morphogenesis Requires the Function of the Segmentation Gene odd-paired. Developmental Biology. 169(2). 580–595. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact